ArticleOncotarget2017
Structurally related odorant ligands of the olfactory receptor OR51E2 differentially promote metastasis emergence and tumor growth.
Article in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 33 citations in OpenAlex.
- Biological effects of a tested commercial fragrance formulation in rats: oxidative and molecular alterations and the protective role of vitamin E.Frontiers in pharmacology · 2026Article
- Overcoming research bias: The untapped potential of biomedically important but understudied proteins.iScience · 2025Article
- Olfactory receptors and human diseases.Cell and tissue research · 2025Review
- Identification of a novel anoikis-related gene signature to predict prognosis and tumor microenvironment in intrahepatic cholangiocarcinoma carcinoma.Discover oncology · 2025Article
- β-Ionone facilitates ex vivo airway smooth muscle relaxation via extraocular opsin-3 light receptor activation.American journal of physiology. Lung cellular and molecular physiology · 2025Article
- Olfactory Receptors and Tumorigenesis: Implications for Diagnosis and Targeted Therapy.Cell biochemistry and biophysics · 2025Review
- Article
- Targeting Odorant Receptors in Adipose Tissue with Food-Derived Odorants: A Novel Approach to Obesity Treatment.Foods (Basel, Switzerland) · 2024Review
- Intracellular Allosteric Antagonist of the Olfactory Receptor OR51E2.Molecular pharmacology · 2024Article
- Transcriptome- and proteome-wide effects of a circular RNA encompassing four early exons of the spinal muscular atrophy genes.Research square · 2024Article
- Identification of Fatty Acid Metabolism-Related Subtypes in Gastric Cancer Aided by Machine Learning.Cancer management and research · 2024Article
- Phylogeny, Ecology, and Gene Families Covariation Shaped the Olfactory Subgenome of Rodents.Genome biology and evolution · 2023Article
- Do Synthetic Fragrances in Personal Care and Household Products Impact Indoor Air Quality and Pose Health Risks?Journal of xenobiotics · 2023Review
- The olfactory receptor OR51E2 activates ERK1/2 through the Golgi-localized Gβγ-PI3Kγ-ARF1 pathway in prostate cancer cells.Frontiers in pharmacology · 2022Article
- Ectopic Odorant Receptor Responding to Flavor Compounds: Versatile Roles in Health and Disease.Pharmaceutics · 2021Review
- Ionone Is More than a Violet's Fragrance: A Review.Molecules (Basel, Switzerland) · 2020Review
- Suppressive Interaction Approach for Masking Stale Note of Instant Ripened Pu-Erh Tea Products.Molecules (Basel, Switzerland) · 2019Article
- Could the Olfactory System Be a Target for Homeopathic Remedies as Nanomedicines?Journal of alternative and complementary medicine (New York, N.Y.) · 2018Article
- Article
- Dynamical Binding Modes Determine Agonistic and Antagonistic Ligand Effects in the Prostate-Specific G-Protein Coupled Receptor (PSGR).Scientific reports · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Olfactory receptors are G protein-coupled receptors. Some of them are expressed in tumor cells, such as the OR51E2 receptor overexpressed in LNCaP prostate cancer cells. It is considered a prostate tumor marker. We previously demonstrated that this receptor is able to promote LNCaP cell invasiveness in vitro upon stimulation with its odorant agonist β-ionone, leading to increased generation of metastases in vivo. In the present study, we show that even a relatively short exposure to β-ionone is sufficient to promote metastasis emergence. Moreover, α-ionone, considered an OR51E2 antagonist, in fact promotes prostate tumor growth in vivo. The combination of α-ionone with β-ionone triggers a higher increase in the total tumor burden than each molecule alone. To support the in vivo results, we demonstrate in vitro that α-ionone is a real agonist of OR51E2, mainly sustaining LNCaP cell growth, while β-ionone mainly promotes cell invasiveness. So, while structurally close, α-ionone and β-ionone appear to induce different cellular effects, both leading to increased tumor aggressiveness. This behaviour could be explained by a different coupling to downstream effectors, as it has been reported for the so-called biased ligands of other G protein-coupled receptors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.